Sudo Biosciences
PrivateLast Round
Series B
Feb 13, 2024
Total Funding Raised
$218M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Sudo Biosciences operates in Healthcare & Life Sciences and is based in Carmel, Indiana. Its latest recorded funding round was a Series B round in February 2024.
Sudo Biosciences is a biopharmaceutical company that develops innovative medicines targeting the TYK2 pseudokinase domain to treat immune-mediated inflammatory conditions, including multiple sclerosis and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sudo Biosciences Comparables
Compare Sudo Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lynk Pharmaceuticals | 88% | |
| Neuron23 | 86% | |
| Alumis | 79% |
For institutional investors. Book with your work email.
Sudo Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 13, 2024 | ||||
| Series B | Dec 20, 2023 | ||||
| Series A | Sep 28, 2022 | ||||
| Seed | Dec 31, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sudo Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Enavate Sciences | Series B |
| Surveyor Capital | Series B |
| Frazier Healthcare Partners | Series A |
| SV Health Investors | Series B |
| Northern Trust | Series B |
| Eventide Funds | Series B |
| Monograph Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors grew 97% MoM, from 1.3K to 2.6K.
- Jul 26, 2026
Monthly visitors increased 232% MoM.
For institutional investors. Book with your work email.
Sudo Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sudo Biosciences's valuation, stock price, and market status.
Is Sudo Biosciences a public or private company?
Sudo Biosciences is a private company.
What is the current stock price of Sudo Biosciences?
Sudo Biosciences is a private company, so its shares have no public market price. Caplight tracks Sudo Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sudo Biosciences worth (valuation)?
Valuation information for Sudo Biosciences is not publicly available.
Can I buy Sudo Biosciences stock?
Sudo Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sudo Biosciences's last funding round?
Sudo Biosciences's most recent funding round was Series B on February 13, 2024.
Who are the main investors in Sudo Biosciences?
Key investors in Sudo Biosciences include Enavate Sciences, Frazier Healthcare Partners, Frazier Life Sciences, The ITG Capital Group, LLC, UPMC Enterprises.
Will Sudo Biosciences IPO soon?
No public IPO plans have been announced for Sudo Biosciences.
How can I track Sudo Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Sudo Biosciences's shares on secondary markets.